Image For Activity Cover
The Lead Episode 48: Influence of monitoring and atrial arrhythmia burden on quality of life and health care utilization in patients undergoing pulsed field ablation.
Deepthy Varghese, MSN, ACNP, FNP, of Northside Hospital, is joined by Sammy Khatib, MD, Ochsner Clinic, Foundation Program, and William Whang, MD, FHRS, Mount Sinai Hospital, to discuss the PULSED AF study investigated the impact of monitoring strategies on atrial arrhythmia (AA) recurrence after pulsed field ablation (PFA) in atrial fibrillation (AF) patients. The study employed various monitoring approaches, including 24-hour Holter monitoring and symptomatic trans telephonic monitoring, revealing that freedom from all AAs varied significantly based on monitoring strategy. PFA demonstrated substantial efficacy, yielding zero burden in 69.4% of paroxysmal AF and 62.2% of persistent AF patients, with a median burden below 9%. Notably, patients with PAF and less than 10% AA burden experienced clinically meaningful quality of life (QoL) improvements, while persistent AF patients showed QoL enhancements regardless of burden. The study suggests that the choice of monitoring protocol influences the ≥30-second AA recurrence endpoint and highlights the association between low AA burden post-PFA, improved QoL, and reduced healthcare utilization related to AAs. Notably, higher AA burden correlated with increased instances of repeat ablations and cardioversions.
Learning Objectives
  • Understanding Monitoring Influence
  • Clinical Correlations in AF Management 
Article Authors and Podcast Contributors
Article Authors
Atul Verma, MD, FHRS, David E. Haines, MD, FHRS, Lucas V. Boersma, MD, Nitesh Sood, MD, Andrea Natale, MD, Francis E. Marchlinski, MD, FHRS, Hugh Calkins, MD, FHRS, Prashanthan Sanders, MBBS, FHRS, Douglas L. Packer, MD, FHRS, Karl-Heinz Kuck, MD, FHRS, Gerhard Hindricks, MD, Hiroshi Tada, MD, FHRS, Robert H. Hoyt, MD, FHRS, James M. Irwin, MD, Jason Andrade, MD, FHRS, Jeffrey Cerkvenik, MS, Jada Selma, PhD, David B. DeLurgio, MD, FHRS 

Podcast Contributors
Deepthy Varghese, MSN, ACNP, FNP, Northside Hospital
Sammy Khatib, MD, Ochsner Clinic, Foundation Program
William Whang, MD, FHRS, Mount Sinai Hospital
Disclosure Policy

ACE Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.


Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.

ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers


All relevant financial relationships have been mitigated.

Host Disclosure(s):
D. Varghese: No relevant financial relationships with ineligible companies to disclose. 

Contributor Disclosure(s):

W. Whang: No relevant financial relationships with ineligible companies to disclose. 
S. Khatib: Honoraria, Speaking, and Consulting: Biotronik, Abbott

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.
ACE Statements
Accreditation Statement
The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians AMA Designation Statement
The Heart Rhythm Society designates this internet-enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Availability: On-Demand
Cost: FREE
Credit Offered:
0.25 ACE Credit
0.25 COP Credit
0.25 ABIM-MOC Point
0.25 ABP-MOC Point
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
© Heart Rhythm Society
Privacy Policy | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
Android App Download IOS App Download Powered By